Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

被引：58

作者：

Medema, Rene H. ^{[1
,2
]}

Lin, Chia-Chi ^{[3
]}

Yang, James Chih-Hsin ^{[3
,4
,5
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands

[3] Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan

[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan

[5] Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan

来源：

CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 20期

关键词：

CELL LUNG-CANCER; PHASE-III TRIAL; SMALL INTERFERING RNA; CHEMOTHERAPY REGIMENS; TUMOR-GROWTH; BI; 2536; PLK1; MUTATIONS; DOCETAXEL; CARBOPLATIN;

D O I：

10.1158/1078-0432.CCR-11-0541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. Clin Cancer Res; 17(20); 6459-66. (C) 2011 AACR.

引用

页码：6459 / 6466

页数：8

共 50 条

[1] Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential
Zhang, Jifa
Zhang, Lele
Wang, Jiaxing
Ouyang, Liang
Wang, Yuxi
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (15) : 10133 - 10160
[2] Developing polo-like kinase 1 inhibitors
Huang, Xufeng
Xie, Zhouling
Liao, Chenzhong
FUTURE MEDICINAL CHEMISTRY, 2020, 12 (10) : 869 - 871
[3] Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1
Berg, Angela
Berg, Thorsten
CHEMBIOCHEM, 2016, 17 (08) : 650 - 656
[4] Polo-like kinase 1 as target for cancer therapy
Lily Weiß
Thomas Efferth
Experimental Hematology & Oncology, 1 (1)
[5] Polo-like kinase 1 as target for cancer therapy
Weiss, Lily
Efferth, Thomas
EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2012, 1
[6] Targeting polo-like kinase 1 for cancer therapy
Klaus Strebhardt
Axel Ullrich
Nature Reviews Cancer, 2006, 6 : 321 - 330
[7] Potential Phytocompounds to Inhibit Human Polo-Like Kinase 1 in Cancer Therapy
Davis, Sangeetha P.
Baby, Bincy
Vipin, A. M.
Kumar, Mala S.
Nazeem, P. A.
RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2015, 6 (06): : 1257 - 1263
[8] Diversity evolution and jump of Polo-like kinase 1 inhibitors
Liao Chenzhong
Yao RiSheng
SCIENCE CHINA-CHEMISTRY, 2013, 56 (10) : 1392 - 1401
[9] Inhibitors of the polo-like protein kinase Plk-1
Nixey, Thomas
Boylan, John
Hulme, C.
Powers, David
Smith, Adrian
Wong, Andrew
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[10] Diversity evolution and jump of Polo-like kinase 1 inhibitors
Chenzhong Liao
RiSheng Yao
Science China Chemistry, 2013, 56 : 1392 - 1401

← 1 2 3 4 5 →